Correction to: Nature Communications https://doi.org/10.1038/s41467-023-43384-y, published online 14 December 2023
The originally published version of this Article contained several errors in references to previous work.
In the Introduction, references 23 and 26 were inadvertently omitted in two sentences, and have been added as follows: ‘The Antibody Mediated Prevention (AMP) trials were the first human efficacy studies of infused bnAbs for HIV-1 prevention (HVTN 704/HPTN 085 and HVTN 703/HPTN 081)23. The efficacy of a CD4-binding site bnAb, VRC01, was tested in men, women and transgender individuals who were vulnerable to HIV-1 in the Americas, sub-Saharan Africa and Europe24–26.’
The published Article incorrectly referenced Cale, E. M. et al. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J Clin Invest 130, 3299–3304, https://doi.org/10.1172/JCI134395 (2020) in a sentence in the Discussion. The correct sentence instead cites reference 39 as follows: ‘The TZM-bl target cell assay used to quantify in vitro neutralization uses cells that are highly permissive to infection39, potentially allowing for larger reductions by VRC01.’
The published Article incorrectly referenced Gaebler, C. et al. Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. J Virol 95, https://doi.org/10.1128/JVI.01986-20 (2021) in a sentence in the Discussion. Gaebler et al. (2021) has been removed from the published Article. The correct sentence instead cites reference 64 as follows: ‘Moreover, the pseudoviruses used in the assay may be more VRC01 sensitive than wild-type viruses64.’
Due to a formatting error of the bibliography, several references were omitted in the published Article. These have been added as follows:
Reference 31 in the Introduction: ‘Viral load has long been associated with HIV-1 pathogenesis and progression31.’
Reference 36 in the Introduction: ‘Previously, breakthrough infections among some PrEP users appear to admit lower viral loads36.’
References 53–56 in the Discussion: ‘Blunting or delaying HIV-1 viremia might be relevant for pathogenesis52, reservoir creation51, viral evolution53, and/or onward transmission during acute infection. Furthermore, small but exciting studies54,55 showed other bnAbs can achieve prolonged (up to 2 years) HIV-1 suppression after stopping ART potentially due to a vaccinal effect in which infused bnAbs interact with virus, e.g., forming immune complexes, to enhance immune control56.’
References 67–69 in the Discussion: ‘Another explanation may be that cell-to-cell transmission of HIV-1 effectively lowers the ability of VRC01 to find virus to neutralize67–69.’
Reference 36 in the Discussion: ‘Viral load blunting and delay was also observed in breakthrough acquisition during ART-mediated prevention trials36.’
References 73–75 in the Discussion: ‘In contrast to ART monotherapy, which rapidly and deterministically leads to viral escape73–75, we show some evidence that bnAb monotherapy is relatively robust.’
References 56, 66 and 79 in the Discussion: ‘Our viral load model does not notably consider cell-to-cell transmission, any enhancement of CD8 T cell killing via VRC01, or any active mechanism whereby VRC01 kills infected cells (such as antibody dependent cellular cytotoxicity or ADCC) and/or mediates phagocytosis66,79. This would be particularly important to know given the hypothesized bnAb vaccinal effect mentioned above56 though it may be less critical here as VRC01 has demonstrated little effector functionality in prior studies66.’
This has been corrected in the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Reeves, D.B., Mayer, B.T., deCamp, A.C. et al. Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun 15, 2575 (2024). https://doi.org/10.1038/s41467-024-46805-8
Published:
DOI: https://doi.org/10.1038/s41467-024-46805-8
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.